Literature DB >> 25375659

Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection.

Rohit B Sangal1, Lynn E Taylor, Fizza Gillani, Athena Poppas, James R Klinger, Corey E Ventetuolo.   

Abstract

RATIONALE: Human immunodeficiency virus (HIV) infection is a risk factor for pulmonary hypertension (PH). Chronic hepatitis C virus (HCV) infection may have unique or synergistic effects on the pulmonary vasculature, but the prevalence and risk factors for PH in HIV-HCV coinfected persons are not known.
OBJECTIVES: To define the prevalence of echocardiographic PH in a cohort of patients with HIV-HCV coinfection, to compare this estimate with the reported prevalence of PH among those with HIV infection alone, and to identify potential risk factors for PH in coinfected individuals.
METHODS: We performed a retrospective study of HIV-HCV coinfected patients followed at our institution from 2003 to 2012 with evidence of HCV infection (positive HCV antibody, measurable HCV ribonucleic acid viral load, and/or genotype) within 6 months of transthoracic echocardiogram. PH was defined by an estimated pulmonary artery systolic pressure (PASP) of greater than or equal to 40 mm Hg or more than moderate right ventricular dysfunction. We excluded those diagnosed with cirrhosis, left ventricular ejection fraction less than 50%, or more than moderate aortic or mitral valve disease.
MEASUREMENTS AND MAIN RESULTS: Sixty-eight patients were included, and 43 had adequate estimates of PASP. The median (interquartile range) age was 52 (48-57) years, and 45 (67%) were men. Eight (19%) had PH, and three (7%) had more than moderate right ventricular dysfunction. After age and sex adjustment, interferon (IFN)-based HCV treatment was associated with higher PASP (β, 6.00 mm Hg; 95% confidence interval, 0.09-11.90; P = 0.047) and with the risk of PH (odds ratio, 5.65; 95% confidence interval, 1.07-29.93; P = 0.042). These associations persisted after adjustment for comorbidities but were attenuated by adjustment for duration of HCV diagnosis.
CONCLUSIONS: The prevalence of echocardiographic PH may be higher in HIV-HCV coinfected individuals than in those with HIV monoinfection. IFN-based HCV treatment and time since HCV diagnosis were associated with the development of PH as assessed by echocardiography. Further studies are needed to examine HIV-HCV coinfection, HCV treatment, and duration of infection as possible causes of pulmonary vascular disease.

Entities:  

Keywords:  echocardiography; hepatitis C; human immunodeficiency virus; interferon; pulmonary hypertension

Mesh:

Year:  2014        PMID: 25375659      PMCID: PMC4298977          DOI: 10.1513/AnnalsATS.201405-225OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  40 in total

1.  Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors.

Authors:  Cleve O James; Ming-Bo Huang; Mafuz Khan; Minerva Garcia-Barrio; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 2.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Authors:  Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelisa
Journal:  Eur J Echocardiogr       Date:  2009-03

Review 3.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

Review 4.  Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report.

Authors:  Sergio Caravita; Maria Beatrice Secchi; Sheng Chin Wu; Simona Pierini; Anita Paggi
Journal:  Cardiology       Date:  2012-01-20       Impact factor: 1.869

Review 5.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

6.  High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.

Authors:  Kristin E Mondy; John Gottdiener; E Turner Overton; Keith Henry; Tim Bush; Lois Conley; John Hammer; Charles C Carpenter; Erna Kojic; Pragna Patel; John T Brooks
Journal:  Clin Infect Dis       Date:  2010-12-09       Impact factor: 9.079

Review 7.  Hepatitis C virus and the lung: implications for therapy.

Authors:  Jonathan Moorman; Mustafa Saad; Semaan Kosseifi; Guha Krishnaswamy
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.

Authors:  Thomas Reiberger; Berit A Payer; Arnulf Ferlitsch; Wolfgang Sieghart; Florian Breitenecker; Maximilian C Aichelburg; Brigitte Schmied; Armin Rieger; Michael Trauner; Markus Peck-Radosavljevic
Journal:  Antivir Ther       Date:  2012-09-05

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

Review 10.  Pharmacology and therapeutic potential of interferons.

Authors:  Peter M George; Rekha Badiger; William Alazawi; Graham R Foster; Jane A Mitchell
Journal:  Pharmacol Ther       Date:  2012-03-28       Impact factor: 12.310

View more
  6 in total

Review 1.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

2.  Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study.

Authors:  Evan L Brittain; Meredith S Duncan; Joyce Chang; Olga V Patterson; Scott L DuVall; Cynthia A Brandt; Kaku A So-Armah; Matthew Goetz; Kathleen Akgun; Kristina Crothers; Courtney Zola; Joon Kim; Cynthia Gibert; Margaret Pisani; Alison Morris; Priscilla Hsue; Hilary A Tindle; Amy Justice; Matthew Freiberg
Journal:  Am J Respir Crit Care Med       Date:  2018-04-01       Impact factor: 21.405

3.  Diagnosis of pulmonary hypertension.

Authors:  Adaani Frost; David Badesch; J Simon R Gibbs; Deepa Gopalan; Dinesh Khanna; Alessandra Manes; Ronald Oudiz; Toru Satoh; Fernando Torres; Adam Torbicki
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 4.  Maintaining lung health with longstanding HIV.

Authors:  Paul Collini; Alison Morris
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

5.  HIV- and HCV-specific markers and echocardiographic pulmonary artery systolic pressure among United States veterans.

Authors:  Courtney E Zola; Meredith S Duncan; Kaku So-Armah; Kristina A Crothers; Adeel A Butt; Cynthia L Gibert; Joon Woo W Kim; Joseph K Lim; Vincent Lo Re; Hilary A Tindle; Matthew S Freiberg; Evan L Brittain
Journal:  Sci Rep       Date:  2020-10-30       Impact factor: 4.379

6.  Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study.

Authors:  Meredith S Duncan; Charles W Alcorn; Matthew S Freiberg; Kaku So-Armah; Olga V Patterson; Scott L DuVall; Kristina A Crothers; Vincent Lo Re; Adeel A Butt; Joseph K Lim; Joon Woo Kim; Hilary A Tindle; Amy C Justice; Evan L Brittain
Journal:  Lancet Healthy Longev       Date:  2021-06-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.